Abstract
Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.
Original language | English (US) |
---|---|
Article number | 168 |
Pages (from-to) | 168 |
Number of pages | 1 |
Journal | Frontiers in Oncology |
Volume | 7 |
Issue number | AUG |
DOIs | |
State | Published - Aug 8 2017 |
Keywords
- Diarrhea
- Gastrointestinal toxicities
- HER2 positive breast cancer
- Pertuzumab
- Rifaximin
- Trastuzumab
ASJC Scopus subject areas
- Oncology
- Cancer Research